Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Outcomes Based on Disease Site in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Squamous Cell Carcinoma

  • By

  • Revadhi C. Chelvarajah

  • Lessandra Y. S. Chee

  • Jie Su

  • Brian O'Sullivan

  • Christopher M. K. L. Yao

  • Enrique Sanz-Garcia

  • Stephen M. Smith

  • Ilan Weinreb

  • Scott Bratman

  • B. C. John Cho

  • Ezra Hahn

  • Andrew Hope

  • Ali Hosni

  • John Kim

  • Andrew McPartlin

  • Nauman Malik

  • Chiaojung Jillian Tsai

  • John de Almeida

  • Anna Spreafico

  • Li Tong

  • Shao Hui Huang

  • John N Waldron

  • March 12, 2026

Share

Objective:

To assess the prevalence and prognostic relevance of p16-positive status in non-oropharyngeal head and neck squamous cell carcinoma (HNSCC).

Approach:
  • Study Population: Identified newly diagnosed, non-metastatic mucosal HNSCC treated curatively between January 2009 and December 2021, excluding nasopharyngeal carcinoma.
  • Assessment of p16 Status: Implemented prospective p16 immunohistochemistry testing for oropharyngeal carcinomas and selected non-oropharyngeal cases, with p16-positivity defined by > 70% tumor cell staining.
  • Statistical Analysis: Compared clinical characteristics and outcomes using descriptive methods and multivariable analysis to evaluate the prognostic value of p16 status.
Key Findings:
  • Outf3061nrphaygelSCi5wdv9b2xm
Interpretation:

The study highlights the need for further investigation into the prognostic implications of p16-positive status in non-oropharyngeal HNSCC due to inconsistent outcomes reported in existing literature.

Limitations:
  • Retrospective design may introduce bias.
  • Limited sample size for p16-positive cases may affect the robustness of findings.
  • Variability in HPV detection methodologies across studies complicates comparisons.
Conclusion:

The study provides insights into the prevalence of p16-positive non-oropharyngeal HNSCC and its clinical characteristics.

Original Source(s)

Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer

  • by Revadhi C. Chelvarajah, Lessandra Y. S. Chee, Jie Su, Brian O'Sullivan, Christopher M. K. L. Yao, Enrique Sanz-Garcia, Stephen M. Smith, Ilan Weinreb, Scott Bratman, B. C. John Cho, Ezra Hahn, Andrew Hope, Ali Hosni, John Kim, Andrew McPartlin, Nauman Malik, Chiaojung Jillian Tsai, John de Almeida, Anna Spreafico, Li Tong, Shao Hui Huang, John N Waldron

  • March 12, 2026

Related Content

Submental Approach Robotic-Assisted Neck Dissection (SARAND) for Minimally Invasive Bilateral Neck Dissection: A Feasibility Cadaver Dissection Study

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma

Ancestry informative genetic variants associated with tobacco metabolic and detoxification capacity measured by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) among smokers